April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Slow-release latanoprost delivery by DSM’s injectable PEA microfibers
Author Affiliations & Notes
  • Jens Thies
    Drug Delivery, DSM Biomedical, Geleen, Netherlands
  • Mirian Gillissen
    Drug Delivery, DSM Biomedical, Geleen, Netherlands
  • Lukasz Koroniak
    Drug Delivery, DSM Biomedical, Geleen, Netherlands
  • George Mihov
    Drug Delivery, DSM Biomedical, Geleen, Netherlands
  • Martina Kropp
    Department of Ophthalmology, University of Genéva, Genéva, Switzerland
  • Gabriele Thumann
    Department of Ophthalmology, University of Genéva, Genéva, Switzerland
  • Footnotes
    Commercial Relationships Jens Thies, DSM Biomedical (E); Mirian Gillissen, DSM Biomedical (E); Lukasz Koroniak, DSM Biomedical (E); George Mihov, DSM Biomedical (E); Martina Kropp, DSM Biomedical (F); Gabriele Thumann, DSM Biomedical (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5256. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jens Thies, Mirian Gillissen, Lukasz Koroniak, George Mihov, Martina Kropp, Gabriele Thumann; Slow-release latanoprost delivery by DSM’s injectable PEA microfibers. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5256.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Since compliance for the treatments for ocular hypertension and glaucoma with topical drugs is poor, sustained dosage forms are critical for more advanced treatment of these diseases. Subconjunctival implantation of (polyester)amide (PEA) microfibers containing drugs currently used to treat ocular hypertension and glaucoma have the potential to safely degrade in the tissue while providing long term delivery of the drug and associated reduction of intraocular pressure. Here we have investigated the release of latanoprost, a prostaglandin analogue used to treat glaucoma, by PEA microfibers in vitro as well as PEA microfiber behavior after subconjunctival and intravitreal implantation.


PEA fibers were prepared by thermal and solvent based processing to construct fibers of 200 µm in diameter and 4-5 mm in length containing 0, 7 or 15 wt% latanoprost. In-vitro release was analyzed by incubation of latanoprost-loaded PEA fibers at 37°C in PBS. Latanoprost release was quantified by HPLC analysis. Ocular biocompatibility was assessed by implantation of PEA fibers subconjunctivally and intravitreally in rabbits.


Latanoprost-loaded microfibers were engineered to release the drug from day 7 to day 35 at a rate of 0.01 µg to 0.5µg latanoprost per day. Previous studies indicated continued release up to six months in-vitro. Biocompatibility of PEA microfibers subconjunctivally and intravitreally was excellent during the 6-month follow up as evidenced by the absence of inflammatory reactions or alteration after complete clinical examination including ERG.


PEA microfibers can be engineered to release drugs over long periods of time. Here we have shown that in vitro PEA microfibers release latanoprost over a period of 35 days and that subconjunctival implantation of PEA microfibers is safe and, therefore, could be useful for the delivery of drugs to treat hypertension and glaucoma.

Keywords: 568 intraocular pressure • 561 injection • 629 optic nerve  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.